Equity awards boost Atea (AVIR) director Barbara Duncan’s holdings

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Atea Pharmaceuticals director Barbara Gayle Duncan increased her equity stake through routine compensation-related transactions. On June 18, 2026, previously granted restricted stock units converted into 29,600 shares of common stock, bringing her direct holdings to 92,350 shares.

She also received new grants covering 37,700 stock options with a $4.36 exercise price, vesting in twelve equal monthly installments through June 18, 2027, and 26,700 restricted stock units that vest in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027, subject to continued service.

Insider Trade Summary

29,600 shares exercised/converted

Mixed 4 txns

Insider DUNCAN BARBARA GAYLE

Role null

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	29,600	$0.00	--
Grant/Award	Restricted Stock Units	26,700	$0.00	--
Grant/Award	Stock Option (Right to Buy)	37,700	$0.00	--
Exercise	Common Stock	29,600	$0.00	--

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct, null); Stock Option (Right to Buy) — 37,700 shares (Direct, null); Common Stock — 92,350 shares (Direct, null)

Footnotes (1)

Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs vested in full on June 18, 2026. The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date. The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date.

Key Figures

RSUs converted to shares: 29,600 shares Shares held after transactions: 92,350 shares New stock options granted: 37,700 options +2 more

5 metrics

RSUs converted to shares 29,600 shares Restricted stock units converting into common stock on June 18, 2026

Shares held after transactions 92,350 shares Direct common stock holdings following June 18, 2026 transactions

New stock options granted 37,700 options Stock options granted on June 18, 2026

Stock option exercise price $4.36 per share Exercise price for 37,700 stock options expiring June 17, 2036

New RSUs granted 26,700 units Restricted stock units granted on June 18, 2026

Key Terms

Restricted Stock Units, RSUs vested in full, stock option, vest in a single installment

4 terms

Restricted Stock Units financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

RSUs vested in full financial

"The RSUs vested in full on June 18, 2026."

stock option financial

"The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026..."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

vest in a single installment financial

"The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting..."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/23/2026 - 05:00 PM Accepted by SEC EDGAR 06/23/2026 - 05:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DUNCAN BARBARA GAYLE

(Last)

(First)

(Middle)

225 FRANKLIN STREET

SUITE 2100

(Street)

BOSTON

MASSACHUSETTS

02110

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Atea Pharmaceuticals, Inc. [ AVIR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/18/2026		M		29,600	A	$0⁽¹⁾	92,350	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	06/18/2026		M			29,600	⁽²⁾	⁽²⁾	Common Stock	29,600	$0	0	D
Restricted Stock Units	⁽¹⁾	06/18/2026		A		26,700		⁽³⁾	⁽³⁾	Common Stock	26,700	$0	26,700	D
Stock Option (Right to Buy)	$4.36	06/18/2026		A		37,700		⁽⁴⁾	06/17/2036	Common Stock	37,700	$0	37,700	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

2. The RSUs vested in full on June 18, 2026.

3. The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date.

4. The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date.

	/s/ Andrea Corcoran, as Attorney-in-Fact for Barbara Gayle Duncan	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Atea Pharmaceuticals (AVIR) report for director Barbara Gayle Duncan?

Atea Pharmaceuticals reported that director Barbara Gayle Duncan had 29,600 restricted stock units convert into common shares and received new grants of 37,700 stock options and 26,700 restricted stock units, all dated June 18, 2026 as part of her equity compensation.

How many Atea Pharmaceuticals (AVIR) shares does Barbara Gayle Duncan hold after these transactions?

After the June 18, 2026 transactions, Barbara Gayle Duncan directly holds 92,350 shares of Atea Pharmaceuticals common stock. This total reflects the conversion of 29,600 restricted stock units into shares and does not include unexercised options or unvested restricted stock units.

What are the terms of Barbara Gayle Duncan’s new stock options at Atea Pharmaceuticals (AVIR)?

Barbara Gayle Duncan received 37,700 stock options with a $4.36 exercise price. These options vest in twelve substantially equal monthly installments following June 18, 2026, becoming fully vested on June 18, 2027, provided she continues her service with Atea Pharmaceuticals through each vesting date.

How do Barbara Gayle Duncan’s new restricted stock units at Atea Pharmaceuticals (AVIR) vest?

She received 26,700 restricted stock units that vest in a single installment on the earlier of the next annual stockholder meeting after June 18, 2026 or June 18, 2027. Vesting is contingent on her continued service with Atea Pharmaceuticals through the applicable vesting date.

Were the Atea Pharmaceuticals (AVIR) insider transactions open-market buys or compensation awards?

The transactions were compensation-related awards and conversions, not open-market purchases or sales. They include the exercise of previously granted restricted stock units into 29,600 shares and new grants of 37,700 stock options and 26,700 restricted stock units to director Barbara Gayle Duncan.